Literature DB >> 17185385

Two sites in the MAPT region confer genetic risk for Guam ALS/PDC and dementia.

Purnima Desai Sundar1, Chang-En Yu, Weiva Sieh, Ellen Steinbart, Ralph M Garruto, Kiyomitsu Oyanagi, Ulla-Katrina Craig, Thomas D Bird, Ellen M Wijsman, Douglas R Galasko, Gerard D Schellenberg.   

Abstract

Unusual forms of amyotrophic lateral sclerosis (ALS-G), Parkinsonism dementia complex (PDC-G) and Guam dementia (GD) are found in Chamorros, the indigenous people of Guam. Neurofibrillary tangles composed of hyperphosphorylated tau are a neuropathologic feature of these closely related disorders. To determine if variation in the gene that encodes microtubule-associated protein tau gene (MAPT) contributes to risk for these disorders, we genotyped nine single nucleotide polymorphism (SNP) sites and one insertion/deletion in the 5' end of MAPT in 54 ALS-G, 135 PDC-G, 153 GD and 258 control subjects, all of whom are Chamorros. Variation at three SNPs (sites 2, 6 and 9) influenced risk for ALS-G, PDC-G and GD. SNP2 acts through a dominant mechanism and is independent of the risk conferred by SNPs 6 and 9, the latter two acting by a recessive mechanism. Persons with the high-risk SNP6 and SNP9 AC/AC diplotype had an increased risk of 3-fold [95% confidence interval (CI)=1.10-8.25] for GD, 4-fold (95% CI=1.40-11.64) for PDC-G and 6-fold (95% CI=1.44-32.14) for ALS-G, compared to persons with other diplotypes after adjusting for SNP2. Carriers of the SNP2 G allele had an increased risk of 1.6-fold (95% CI=1.00-2.62) for GD, 2-fold (95% CI=1.28-3.66) for PDC-G, and 1.5-fold (95% CI=0.74-3.00) for ALS-G, compared to non-carriers after adjusting for SNPs 6 and 9. Others have shown that SNP6 is also associated with risk for progressive supranuclear palsy. These two independent cis-acting sites presumably influence risk for Guam neuro-degenerative disorders by regulating MAPT expression.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17185385     DOI: 10.1093/hmg/ddl463

Source DB:  PubMed          Journal:  Hum Mol Genet        ISSN: 0964-6906            Impact factor:   6.150


  22 in total

1.  Quantitative proteomics identifies surfactant-resistant alpha-synuclein in cerebral cortex of Parkinsonism-dementia complex of Guam but not Alzheimer's disease or progressive supranuclear palsy.

Authors:  Wan Yang; Randall L Woltjer; Izabela Sokal; Catherine Pan; Yan Wang; Mary Brodey; Elaine R Peskind; James B Leverenz; Jing Zhang; Daniel P Perl; Douglas R Galasko; Thomas J Montine
Journal:  Am J Pathol       Date:  2007-08-03       Impact factor: 4.307

2.  Structural and functional characterization of H2 haplotype MAPT promoter: unique neurospecific domains and a hypoxia-inducible element would enhance rationally targeted tauopathy research for Alzheimer's disease.

Authors:  Bryan Maloney; Debomoy K Lahiri
Journal:  Gene       Date:  2012-01-30       Impact factor: 3.688

3.  Identification of novel susceptibility loci for Guam neurodegenerative disease: challenges of genome scans in genetic isolates.

Authors:  Weiva Sieh; Yoonha Choi; Nicola H Chapman; Ulla-Katrina Craig; Ellen J Steinbart; Joseph H Rothstein; Kiyomitsu Oyanagi; Ralph M Garruto; Thomas D Bird; Douglas R Galasko; Gerard D Schellenberg; Ellen M Wijsman
Journal:  Hum Mol Genet       Date:  2009-06-30       Impact factor: 6.150

4.  Inherited and somatic mitochondrial DNA mutations in Guam amyotrophic lateral sclerosis and parkinsonism-dementia.

Authors:  Dana M Reiff; Rita Spathis; Chim W Chan; Miguel G Vilar; Krithivasan Sankaranarayanan; Daniel Lynch; Emily Ehrlich; Samantha Kerath; Risana Chowdhury; Leah Robinowitz; J Koji Lum; Ralph M Garruto
Journal:  Neurol Sci       Date:  2011-08-06       Impact factor: 3.307

Review 5.  A critical review of the postulated role of the non-essential amino acid, β-N-methylamino-L-alanine, in neurodegenerative disease in humans.

Authors:  N Chernoff; D J Hill; D L Diggs; B D Faison; B M Francis; J R Lang; M M Larue; T-T Le; K A Loftin; J N Lugo; J E Schmid; W M Winnik
Journal:  J Toxicol Environ Health B Crit Rev       Date:  2017-06-09       Impact factor: 6.393

6.  Tau pathology involves protein phosphatase 2A in parkinsonism-dementia of Guam.

Authors:  Mohammad Arif; Syed Faraz Kazim; Inge Grundke-Iqbal; Ralph M Garruto; Khalid Iqbal
Journal:  Proc Natl Acad Sci U S A       Date:  2014-01-06       Impact factor: 11.205

Review 7.  Advances in the genetics of Parkinson disease.

Authors:  Joanne Trinh; Matt Farrer
Journal:  Nat Rev Neurol       Date:  2013-07-16       Impact factor: 42.937

8.  C9orf72 hexanucleotide repeat expansion and Guam amyotrophic lateral sclerosis-Parkinsonism-dementia complex.

Authors:  Beth A Dombroski; Douglas R Galasko; Ignacio F Mata; Cyrus P Zabetian; Ulla-Katrina Craig; Ralph M Garruto; Kiyomitsu Oyanagi; Gerard D Schellenberg
Journal:  JAMA Neurol       Date:  2013-06       Impact factor: 18.302

9.  Tau isoform regulation is region- and cell-specific in mouse brain.

Authors:  Pamela McMillan; Elena Korvatska; Parvoneh Poorkaj; Zana Evstafjeva; Linda Robinson; Lynne Greenup; James Leverenz; Gerard D Schellenberg; Ian D'Souza
Journal:  J Comp Neurol       Date:  2008-12-20       Impact factor: 3.215

10.  H2 haplotype at chromosome 17q21.31 protects against childhood sexual abuse-associated risk for alcohol consumption and dependence.

Authors:  Elliot C Nelson; Arpana Agrawal; Michele L Pergadia; Jen C Wang; John B Whitfield; F Scott Saccone; Jason Kern; Julia D Grant; Andrew J Schrage; John P Rice; Grant W Montgomery; Andrew C Heath; Alison M Goate; Nicholas G Martin; Pamela A F Madden
Journal:  Addict Biol       Date:  2010-01       Impact factor: 4.280

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.